A statement released earlier today by Zacks Investment Research about ABIOMED, Inc. (NASDAQ:ABMD) bumps the target price to $138.00
- Updated: September 16, 2016
Just yesterday ABIOMED, Inc. (NASDAQ:ABMD) traded 1.02% higher at $123.96. ABIOMED, Inc.’s 50-day average is $119.79 and its two hundred day moving average is $104.66. The last stock price close is up 18.89% relative to the 200-day moving average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same time period. 128,474 shares of the stock were exchanged, down from ann avg. trading volume of 551,385.
Reporting a possible upside of 0.11%, Zacks Investment Research upped the target stock price of ABIOMED, Inc. (NASDAQ:ABMD) to $138
On 7/29/2016, Jefferies & Co released a statement for ABIOMED, Inc.(NASDAQ:ABMD) upped the target price from $125.00 to $130.00. At the time, this indicated a possible upside of 0.10%.
Recent Performance Chart:
Also covering ABIOMED, Inc.’s stock price target, a total of 8 brokerages have issued a ratings update on ABMD. The one year target stock price is $119.25 with five firms rating the company a strong buy, two firms rating the company a buy, two analysts rating the stock a hold, 0 rating the company to underperform, and finally 0 analysts rating the stock as sell.
ABIOMED, Inc. has a one-year low of $67.81 and a one-year high of $124.72 with a P/E ratio of 132. ABIOMED, Inc.’s total market value is currently $0.0.
About ABIOMED, Inc. (NASDAQ:ABMD)
ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, and the hybrid lab and in the heart surgery suite by heart surgeons.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.